Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma
BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.
Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC
A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.
2 Clarke Drive Cranbury, NJ 08512